Skip to main content
OpenTrials
Completed

NCT Number: NCT03643614

Autologous Adipose-derived Regenerative Cells Injection for Treatment of Radiation-induced Rectovaginal Fistula

A new strategy for treatment of late radiation damage is to develop methods aimed at stimulating the regenerative capabilities of irradiated tissues. Since the main pathogenetic mechanism of the development of late radiation damage is the death or damage of the replicative mechanism of stromal cells (SC), a justified approach can be considered as transplantation of intact SC. Currently, there is convincing evidence in the scientific literature that the injection of intact autologous SCs into the zone of fibrosis surrounding the chronic radiation ulcer leads to the healing of a wound defect.

An Initiative Clinical Trial. Introduction of autologous regenerative cells of adipose tissue for the treatment of post-irradiation vaginal-rectal fistula. It is assumed that patients will be included in the project within 12 months; the monitoring of each patient will last for 6 months; the total duration of the clinical part of the study will be 18 months; The total duration of the clinical trial including the preparatory phase and the writing of the report is about 24 months. It is assumed that at least 16 patients aged 20 to 75 years who have verified diagnosis of post-irradiation vaginal-rectal fistula will participate in this pilot project. The aims of the clinical trial are to preliminarily assess the safety, effectiveness and quality of life of patients after introducing autologous regenerative cells of adipose tissue for the treatment of post-irradiation vaginal-rectal fistula.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rectovaginal Fistula Digestive System Diseases Digestive System Fistula Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Fistula Gastrointestinal Diseases Genital Diseases Genital Diseases, Female Intestinal Diseases Intestinal Fistula Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Rectal Diseases Rectal Fistula Urogenital Diseases Vaginal Diseases Vaginal Fistula

Age range

20 year–75 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

South Ural State Medical University

Chelyabinsk, Chelyabinsk Oblast, 454092, Russia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of radiation-induced rectovaginal fistula established at least six months after radiation therapy
  • Absence of oncological disease relapse during whole observation period
  • Absence of rectal and anal cancer
  • Patient have read and signed informed consent

Exclusion criteria

  • Contraindications for local/general anesthesia or a history of anesthetic medicines allergy
  • Acute hemorrhoid or anal fissure
  • Acute purulent paraproctitis
  • Inflammatory colon diseases
  • History of extensive posttraumatic or postoperative alterations which causes obstacles to follow protocol examination
  • Chronic sub- or decompensated internal organs diseases
  • Clinically significant laboratory tests abnormalities
  • Conditions that limits patient compliance (dementia, psycho-neurological diseases, drug abuse, alcohol abuse etc.)
  • Patients involved in other clinical trials or taking medications under research during last three months
  • Cancer patients including postoperative chemo- or/and radiotherapy at least three months after surgery
  • Patients with increased activated partial thromboplastin time level 1,8 times above normal
  • Patients who take anticoagulants or took anticoagulants at least one month before including into trial
  • Patients who take or took before investigation glycoprotein inhibitors IIB/IIIA
  • Patients with history of taking medications that influence fatty tissue structure

Treatment and study plan

Injection of autologous regenerative cells of adipose tissue

Procedure

Autologous regenerative cells of adipose tissue obtained by enzymatic digestion of lipoaspirate are injected diffusively in the submucosal plane of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.

Primary outcomes

  1. Serious adverse events

    Time frame: 4 weeks after injection of adipose-derived regenerative cells

    Frequency, type and severity of serious adverse events (SAE)

  2. Serious adverse reactions

    Time frame: 4 weeks after injection of adipose-derived regenerative cells

    Frequency, type and severity of serious adverse reactions (SAR)

Secondary outcomes

  1. Changes of fistula size

    Time frame: 48 weeks after intervention

    Intervention impact on dimensions of rectovaginal fistula

  2. Changes in rectovaginal soft tissue density and flexibility

    Time frame: 48 weeks after intervention

    Intervention impact on soft tissue density and flexibility assessed by ultrasound elastography

  3. Quality of life monitoring - 1

    Time frame: 48 weeks after intervention

    Quality of life estimated by validated questionnaire: The Short Form (36) Health Survey (SF-36). SF-36 is a 36-item, patient-reported survey of patient health.

    The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    The eight sections are:

    • vitality
    • physical functioning
    • bodily pain
    • general health perceptions
    • physical role functioning
    • emotional role functioning
    • social role functioning
    • mental health

  4. Quality of life monitoring - 2

    Time frame: 48 weeks after intervention

    Quality of life estimated by validated questionnaire. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C-30 with module for proctitis-23 is a questionnaire developed to assess the proctitis-specific quality of life of cancer patients. Each subscale values varies from 1 to 4. Lower values represents better life quality. Total score is computed by summarizing of subscales.

Sponsors and collaborators

Lead sponsor

South Ural State Medical University

Other

Registry information

Official study title

Evaluation of Effectiveness and Safety of Autologous Adipose-derived Regenerative Cells Injection for Treatment of Radiation-induced Rectovaginal Fistula

Important dates

Study start
2017
Primary completion
2019
Study completion
2020
First posted
Aug 23, 2018
Registry last updated
Jan 27, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.